Testosterone Cypionate: Mitigating Chronic Pain in Hypogonadal U.S. Men
Reading Time: < 1 minute Introduction Chronic pain affects over 50 million American adults, with men comprising a significant portion due to occupational hazards, sports injuries, and age-related musculoskeletal degeneration. Testosterone deficiency, or hypogonadism, is prevalent in up to 40% of aging U.S. males, correlating with heightened pain sensitivity and opioid dependency. Testosterone cypionate, a long-acting intramuscular ester of testosterone, has emerged as a promising adjunct in pain management. This article evaluates its efficacy in mitigating chronic pain and reducing analgesic requirements, drawing from clinical data tailored to American male demographics. Prevalence of Hypogonadism and Chronic Pain in American Males In the United States, the...


